EcoR1 Capital’s Immunovant IMVT Stock Holding History

EcoR1 Capital’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,140,819	Closed	-$9.72M	–	92
2021 Q4	$9.72M	Hold	1,140,819	–	–	0.31%	38
2021 Q3	$9.91M	Buy	+1,140,819	New	+$10.3M	0.34%	34

Other funds holding IMVT

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

AGM

Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EcoR1 Capital's IMVT Position: Q1 2022 in Review

EcoR1 Capital sold out of Immunovant (IMVT) in Q1 2022, closing a stake of 1,140,819 shares — an estimated $9.72M sold.

EcoR1 Capital first reported a position in IMVT in Q3 2021 and held it in 2 quarters. The position peaked at $9.91M in Q3 2021. 112 funds tracked by Wall St. Rank hold IMVT as of Q1 2022.

EcoR1 Capital reported no remaining Immunovant position as of Q1 2022 after selling out during the quarter.
EcoR1 Capital sold 1,140,819 Immunovant shares in Q1 2022, an estimated $9.72M.
EcoR1 Capital first reported a position in Immunovant in Q3 2021 and held it in 2 quarters.
EcoR1 Capital's Immunovant position peaked at $9.91M in Q3 2021.
112 funds tracked by Wall St. Rank held Immunovant as of Q1 2022.

Based on EcoR1 Capital's 13F filing for Q1 2022, filed 16 May 2022.